Associates of an Elevated Natriuretic Peptide Level in Stable Heart Failure Patients: Implications for Targeted Management
暂无分享,去创建一个
P. Collier | C. Watson | K. McDonald | J. Baugh | A. Jan | N. Murphy | M. Ledwidge | Ian R Dawkins | Ian Dawkins
[1] C. Watson,et al. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. , 2013, JAMA.
[2] R. Akdemir,et al. Changes in Serum Natriuretic Peptide Levels after Percutaneous Closure of Small to Moderate Ventricular Septal Defects , 2012, TheScientificWorldJournal.
[3] M. Böhm,et al. Biomarkers: optimizing treatment guidance in heart failure , 2011, Clinical Research in Cardiology.
[4] D. Moertl,et al. N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study. , 2010, Journal of the American College of Cardiology.
[5] C. Frampton,et al. N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. , 2009, Journal of the American College of Cardiology.
[6] D. Phelan,et al. Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. , 2009, Journal of the American College of Cardiology.
[7] E. Okello,et al. Treatment with spironolactone for 24 weeks decreases the level of matrix metalloproteinases and improves cardiac function in patients with chronic heart failure of ischemic etiology. , 2009, The Canadian journal of cardiology.
[8] H. Nakahama,et al. Impact of left ventricular end-diastolic wall stress on plasma B-type natriuretic peptide in heart failure with chronic kidney disease and end-stage renal disease. , 2009, Clinical chemistry.
[9] A. Cohen-Solal,et al. Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure. , 2009, Journal of the American College of Cardiology.
[10] D. Moertl,et al. B-type natriuretic peptide predicts benefit from a home-based nurse care in chronic heart failure. , 2009, Journal of cardiac failure.
[11] G. Filippatos,et al. Determinants of plasma NT-pro-BNP levels in patients with atrial fibrillation and preserved left ventricular ejection fraction , 2009, Clinical Research in Cardiology.
[12] Peter Buser,et al. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. , 2009, JAMA.
[13] Gianni Tognoni,et al. Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). , 2008, Journal of the American College of Cardiology.
[14] J. Svendsen,et al. ANP and BNP in atrial fibrillation before and after cardioversion--and their relationship to cardiac volume and function. , 2008, International journal of cardiology.
[15] T. Inomata,et al. Prognostic utility of B-type natriuretic peptide assessment in stable low-risk outpatients with nonischemic cardiomyopathy after decompensated heart failure. , 2008, Journal of the American College of Cardiology.
[16] C. Phillips,et al. Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. , 2007, Journal of the American College of Cardiology.
[17] A. Cohen-Solal,et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. , 2007, Journal of the American College of Cardiology.
[18] R. Rodeheffer,et al. Alternate circulating pro-B-type natriuretic peptide and B-type natriuretic peptide forms in the general population. , 2007, Journal of the American College of Cardiology.
[19] Kenneth McDonald,et al. Diastolic Heart Failure: Evidence of Increased Myocardial Collagen Turnover Linked to Diastolic Dysfunction , 2007, Circulation.
[20] Y. Kihara,et al. B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. , 2006, Journal of the American College of Cardiology.
[21] Richard B Devereux,et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardio , 2005, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.
[22] H Robert Bergen,et al. Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[23] A. Dobson,et al. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review , 2005, BMJ : British Medical Journal.
[24] J. Bartunek,et al. Wall stress modulates brain natriuretic peptide production in pressure overload cardiomyopathy. , 2004, Journal of the American College of Cardiology.
[25] Satoko Nakamura,et al. Diagnostic and prognostic value of plasma brain natriuretic peptide in non-dialysis-dependent CRF. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[26] N. Lamblin,et al. B-type natriuretic peptide and peak exercise oxygen consumption provide independent information for risk stratification in patients with stable congestive heart failure. , 2004, Journal of the American College of Cardiology.
[27] Gabriel Thabut,et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. , 2004, Journal of the American College of Cardiology.
[28] J. Knowles,et al. Ventricular expression of natriuretic peptides in Npr1(-/-) mice with cardiac hypertrophy and fibrosis. , 2002, American journal of physiology. Heart and circulatory physiology.
[29] M. Vogeser,et al. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. , 2001, Journal of the American College of Cardiology.
[30] F. Alla,et al. Limitation of Excessive Extracellular Matrix Turnover May Contribute to Survival Benefit of Spironolactone Therapy in Patients With Congestive Heart Failure: Insights From the Randomized Aldactone Evaluation Study (RALES) , 2000, Circulation.
[31] Kenji Nakamura,et al. Cardiac fibrosis in mice lacking brain natriuretic peptide. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[32] C. Frampton,et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations , 2000, The Lancet.
[33] A. Struthers,et al. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. , 1997, Cardiovascular research.
[34] L. Stevenson,et al. The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. , 1989, JAMA.
[35] N. Reichek,et al. Noninvasive Determination of Left Ventricular End‐systolic Stress: Validation of the Method and Initial Application , 1982, Circulation.
[36] J. Ferrières,et al. Usefulness of Inhospital Change in B‐Type Natriuretic Peptide Levels in Predicting Long‐Term Outcome in Elderly Patients Admitted for Decompensated Heart Failure , 2007 .